The Battle For Cannabidiol (CBD): Big Pharma VS The People
Posted on 25 May 2016
The medicinal properties of cannabidiol (better known as CBD), a compound found in the Cannabis sativa L. plant species, are quickly drawing the attention of scientists, plant-medicine lovers, dietary-supplement companies, venture capitalists, professional athletes, and Big Pharma — not to mention people living with serious, chronic medical conditions. Insiders predict the burgeoning market will be as profitable as the NFL.
Today, if you run a search on PubMed.gov, a medical research database, you’ll find 1,501 academic articles on cannabidiol.
Unlike tetrahydrocannabinol (THC), CBD has no euphoric properties whatsoever, and carries no street value. What it does offer, however, are a host of health benefits. According to a 2013 review published in the British Journal of Clinical Pharmacology, CBD has been shown to reduce pain and inflammation and also has anticonvulsant, anti-inflammatory, anti-tumor and antidepressant properties.
For full article please visit: http://www.honeycolony.com/article/the-battle-for-cannabidiol-cbd/